In this short communication we describe the phenomenon of multidrug-resistant HIV-1 infection, possible causes and treatment op-tions in these cases. The case report presents the successful use of a drug lenacapavir in a non-adherent patient with HIV infection trea-ted at the HIV center of the Clinic of Infectious Diseases, University Hospital Bulovka, Prague.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
[Alternative treatment options for multidrug-resistant HIV-1 infection - first use of lenacapavir in the Czech Republic].
Klin Mikrobiol Infekc Lek
June 2024
Clinic of Infectious Diseases, Bulovka University Hospital, 1st, 2nd and 3rd Faculty of Medicine, Charles University, Czech Republic, e-mail:
In this short communication we describe the phenomenon of multidrug-resistant HIV-1 infection, possible causes and treatment op-tions in these cases. The case report presents the successful use of a drug lenacapavir in a non-adherent patient with HIV infection trea-ted at the HIV center of the Clinic of Infectious Diseases, University Hospital Bulovka, Prague.
View Article and Find Full Text PDFPeople with four-class drug-resistant HIV-1 may have low levels of intact DNA.
AIDS
March 2025
San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), IRCCS San Raffaele Scientific Institute, Milan, Italy.
We evaluated the HIV-1 reservoir in people with four-class drug-resistant (4DR) virus compared with those without drug resistance. Using the intact proviral DNA assay, we found that both groups had similar levels of intact HIV-1 DNA, suggesting that multidrug-resistant HIV does not significantly alter the size of the reservoir. These findings are a first step in studying the HIV-1 reservoir in the population with multidrug-resistant virus, and further studies are needed to confirm our results.
View Article and Find Full Text PDFLeronlimab Treatment for Multidrug-Resistant HIV-1 (OPTIMIZE): a Randomized, Double-Blind, Placebo-Controlled Trial.
J Acquir Immune Defic Syndr
February 2025
CytoDyn Inc., 1111 Main Street Suite 660, Vancouver, WA 98660.
Background: Leronlimab is a humanized κ-IgG4 monoclonal antibody that blocks C-C chemokine receptor type 5 (CCR5). We investigated leronlimab as a treatment option for people living with multidrug-resistant HIV-1.
Setting: and Methods: In a phase 2b/3, multicenter, randomized, double-blind, placebo-controlled study conducted in 21 hospital centers in the United States, treatment-experienced people living with HIV (PLWH) with documented drug resistance were randomly assigned once weekly leronlimab (350 mg subcutaneously) or matching placebo for one week overlapping existing failing antiretroviral treatment (ART), followed by a 24-week single-arm extension with weekly leronlimab combined with a new optimized background treatment (OBT).
Resistance Analyses in Heavily Treatment-Experienced People with HIV Treated with the Novel HIV Capsid Inhibitor Lenacapavir After 2 years.
J Infect Dis
January 2025
Gilead Sciences, Inc., 333 Lakeside Dr., Foster City, CA, 94404 USA.
Background: Lenacapavir is a highly potent first-in-class inhibitor of HIV-1 capsid approved for the treatment of heavily treatment-experienced (HTE) people with HIV-1 (PWH) harboring multidrug resistant (MDR) virus, in combination with an optimized background regimen (OBR). Resistance analyses conducted after 2 years of lenacapavir treatment in the phase 2/3 CAPELLA study are described.
Methods: CAPELLA enrolled viremic HTE PWH with resistance to 2 or more drugs per class in at least 3 of the 4 main drug classes.
Efficacy and safety of an Albuvirtide-based regimen for preventing mother-to-child transmission of multidrug-resistant HIV: a case report.
BMC Pregnancy Childbirth
January 2025
Department of Infectious Diseases, Ganzhou Fifth People's Hospital, Ganzhou, China.
Background: Antiretroviral drugs are essential for preventing mother-to-child transmission (MTCT) of HIV in HIV-infected pregnant women. However, ART treatment for HIV-infected pregnant women with multidrug resistance remains a major challenge. Effective and safe ART regimens for preventing MTCT should be tailored to this special population.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!